Welcome to Simcyp


population based pharmacokinetic modelling and simulation

home > research & development > publications > posters / abstracts


Posters / Abstracts

Simcyp Posters RSS

Please view our latest posters below:


  • Burt H et al.

    Mar 2013

    An assessment of the OCT2/MATE transporter mediated DDI between metformin and cimetidine using a mechanistic kidney model (Mech KiM).
    AAPS Transporters Workshop on Drug Transporters in ADME: from Bench to Bedside
    Bethesda MD, USA, March 17th-20th 2013

    Download poster

  • Polak S et al.

    Mar 2013

    Prediction of skin disposition after topical application of drugs – Simcyp platform as a tool for capturing system information and safety assessment.
    Society of Toxicology Annual Meeting 2013
    San Antonio TX, USA, March 10th-14th 2013

    Download poster

  • Darwich AS et al.

    Mar 2013

    Application of an in silico physiologically based pharmacokinetic model to simulate oral drug biovariability of atorvastatin acid and cyclosporine post bariatric surgery.
    114th ASCPT Meeting
    Indianapolis IN, USA, 5th-9th March, 2013

    Download poster

  • Humphries HE et al.

    Mar 2013

    Application of physiologically based pharmacokinetic (PBPK) modelling for prediction of complex drug-drug interactions (DDIs involving inhibition of OATP1B1-mediated uptake and CYP2C8 metabolism by gemfibrozil and its major metabolite gemfibrozil 1-O-ß glucuronide.
    114th ASCPT Meeting
    Indianapolis IN, USA, 5th-9th March, 2013

    Download poster

  • Rowland-Yeo K et al.

    Mar 2013

    Application of physiologically based pharmacokinetic (PBPK) modeling for prediction of the drug-drug Interaction (DDI) between paroxetine and terbinafine in a Japanese population.
    114th ASCPT Meeting
    Indianapolis IN, USA, 5th-9th March, 2013

    Download poster

  • Lu G et al.

    Nov 2012

    Application of Simcyp to simulate PK as well as response of nifedipine in Japanese and Caucasian populations.
    27th JSSX Annual Meeting
    Tokyo, Japan, November 20th-22nd 2012

    Download poster

  • Abduljalil K et al.

    Oct 2012

    Physiologically based PK/PD modelling to predict ibuprofen exposure response in paediatrics.
    14th VKliPha Annual Conference
    Rostock, Germany, October 14th-20th 2012

    Download poster

  • Bajot F et al.

    Oct 2012

    A dynamic physiologically-based pharmacokinetic (PBPK) model to predict the disposition of
    rosuvastatin in human and the extent of drug-drug interactions.
    AAPS Annual Meeting 2012
    Chicago IL, USA, October 14th-18th 2012

    Download poster

  • Hatley O et al.

    Oct 2012

    The rat as a model for screening intestinal metabolism potential.
    AAPS Annual Meeting 2012
    Chicago IL, USA, October 14th-18th 2012

    Download poster

  • Li L et al.

    Oct 2012

    Development of a minimal-PBPK model for simulating monoclonal antibody pharmacokinetics in humans.
    AAPS Annual Meeting 2012
    Chicago IL, USA, October 14th-18th 2012

    Download poster

  • Patel N et al.

    Oct 2012

    Mechanistic deconvolution using the ADAM model: Part 1. Establishing mechanistic IVIVC for controlled release formulations of the high extraction BCS Class I drug metoprolol: comparison with conventional IVIVC models.
    AAPS Annual Meeting 2012
    Chicago IL, USA, October 14th-18th 2012

    Download poster

  • Patel N et al.

    Oct 2012

    Mechanistic Deconvolution Using the ADAM Model: Part 2. Designing a new once daily formulation for metoprolol based on mechanistic IVIVC and studying the population variability in its pharmacokinetics.
    AAPS Annual Meeting 2012
    Chicago IL, USA, October 14th-18th 2012

    Download poster

  • Patel N et al.

    Oct 2012

    Quantitative prediction of formulation-specific food effects for BCS/BDDCS Class II drug Nifedipine and population variability of its pharmacokinetics using the ADAM model within the Simcyp Simulator.
    AAPS Annual Meeting 2012
    Chicago IL, USA, October 14th-18th 2012

    Download poster

  • Salem F et al.

    Sep 2012

    Mapping in vitro and in vivo derived CYP3A ontogeny function: a critical comparison between various ontogeny models.
    ACCP Annual Meeting 2012
    San Diego CA, USA, September 23rd-25th 2012

    Download poster

  • Darwich A et al.

    Sep 2012

    Development and application of a mechanistic physiologically based pharmacokinetic model to assess oral drug availability post bariatric surgery in morbidly obese patients.
    ACCP Annual Meeting 2012
    San Diego CA, USA, September 23rd-25th 2012

    Download poster

  • Burt HJ et al.

    Sep 2012

    A comparison of single species allometric methods for the prediction of renal clearance in man.
    13th Annual Simcyp Consortium Meeting
    Sheffield, UK, 17th-19th September 2012

    Download poster

  • Patel N et al.

    Sep 2012

    Quantitative prediction of formulation-specific food effects for BCS/BDDCS Class II drug nifedipine and population variability of its pharmacokinetics using the ADAM model within the Simcyp Simulator.
    13th Annual Simcyp Consortium Meeting
    Sheffield, UK, 17th-19th September 2012

    Download poster

  • Salem F et al.

    Sep 2012

    A critical comparison between CYP1A2 and 3A4 ontogeny profiles used in pediatric PBPK models.
    1st World Conference of Pharmacometrics
    Seoul, Korea, September 5th-7th 2012

    Download poster

  • Vajjah P et al.

    Sep 2012

    PBPK/PD approach to discern potential sex and ethnic differences in the time course of QT prolongation following quinidine administration: Caucasian vs Korean healthy populations.
    1st World Conference of Pharmacometrics
    Seoul, Korea, September 5th-7th 2012

    Download poster

  • Rostami-Hodjegan A et al.

    Sep 2012

    Top-down modeling meets bottom-up modeling: the physiological and physicochemical basis for the ontogeny of UGT2B7-mediated drug glucuronidation.
    1st World Conference of Pharmacometrics
    Seoul, Korea, September 5th-7th 2012

    Download poster

  • Grist EPM et al.

    Sep 2012

    Application of the target-mediated drug disposition approach within a minimal PBPK model to investigate pharmacokinetics of therapeutic proteins.
    1st World Conference of Pharmacometrics
    Seoul, Korea, September 5th-7th 2012

    Download poster

  • Rose R et al.

    Sep 2012

    Application of a PBPK/PD model describing the change in systolic blood pressure following administration of immediate release and controlled release nifedipine formulations.
    1st World Conference of Pharmacometrics
    Seoul, Korea, September 5th-7th 2012

    Download poster

  • Burt H et al.

    Jul 2012

    Simulation of the effect of urine pH on renal drug clearance using a novel population based mechanistic kidney model (Mech KiM).
    Gordon Research Conference – Drug Metabolism
    Holderness NH, USA, 8th-13th July, 2012

    Download poster

  • Barter ZE et al.

    Jun 2012

    What is the contribution of CYP2B6 to bupropion metabolic clearance? Implications for the prediction of CYP2B6 mediated drug-drug interactions.
    19th MDO/12th European ISSX Meeting
    Noordwijk aan Zee, Netherlands, 17th-21st June 2012

    Download poster

  • Salem F et al.

    Jun 2012

    Mapping in vitro and in vivo derived CYP3A ontogeny function: a critical comparison between various ontogeny models.
    PAGE 2012 Meeting
    Venice, Italy, 5th-8th June 2012

    Download poster

  • Rose R et al.

    Jun 2012

    Prediction of the hypnotic effects of zolpidem by extrapolation of a mechanism-based PKPD model developed for triazolam in healthy volunteers.
    PAGE 2012 Meeting
    Venice, Italy, 5th-8th June 2012

    Download poster

  • Mishra H et al.

    Jun 2012

    Model-based prediction of domperidone and ketoconazole interaction and its impact on QTc proglongation.
    PAGE 2012 Meeting
    Venice, Italy, 5th-8th June 2012

    Download poster

  • Chetty M et al.

    Jun 2012

    A systems approach to predicting differences in pharmacological response to a CYP1A2 substrate, resulting from pharmacokinetic differences in non-smokers, passive smokers and heavy smokers.
    PAGE 2012 Meeting
    Venice, Italy, 5th-8th June 2012

    Download poster

  • Abduljalil K et al.

    Jun 2012

    Predicting the developmental PK/PD of cyclosporine (CsA) in paediatrics.
    PAGE 2012 Meeting
    Venice, Italy, 5th-8th June 2012

    Download poster

  • Darwich A et al.

    Jun 2012

    Development and application of a mechanistic physiologically based pharmacokinetic model to assess oral drug availability post bariatric surgery in morbidly obese patients.
    PAGE 2012 Meeting
    Venice, Italy, 5th-8th June 2012

    Download poster

  • Lu G et al.

    Jun 2012

    Application of the Simcyp PBPK/PD model to simulate PK and PD of nifedipine in Japanese populations.
    PAGE 2012 Meeting
    Venice, Italy, 5th-8th June 2012

    Download poster

  • Vajjah P et al.

    Jun 2012

    Prediction of serum and certebrospinal fluid concentrations of carbamazepine: an application of parameter estimation and the permeability limited 4-compartment brain model in Simcyp.
    PAGE 2012 Meeting
    Venice, Italy, 5th-8th June 2012

    Download poster

  • Li L et al.

    May 2012

    Development of a minimal-PBPK model for simulating monclonal antibody pharmacokinetics in human.
    AAPS National Biotechnology Conference
    San Diego CA, USA, 21st-23rd May 2012

    Download poster

  • Patel N et al.

    Mar 2012

    Population-based mechanistic modelling of absorption of the BCS/BDDCS Class II drug nifedipine: quantitative prediction of formulation-specific food effects.
    8th PBP World Meeting
    Istanbul, Turkey, 19th-22nd March 2012

    Download poster

  • Almond L et al.

    Mar 2012

    Assessment of the induction of systemic clearance versus first-pass effect of midazolam (MDZ) using a physiologically-based dynamic model.
    113th ASCPT Meeting
    National Harbor MD, USA, 14th-17th March 2012

    Download poster

  • Siccardi M et al.

    Mar 2012

    Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using a physiologically-based dynamic model.
    113th ASCPT Meeting
    National Harbor MD, USA, 14th-17th March 2012

    Download poster

  • Neuhoff S et al.

    Mar 2012

    Prediction of the Impact of P-gp-Mediated Efflux on the Dose Proportionality of Digoxin Bioavailability.
    113th ASCPT Meeting
    National Harbor MD, USA, 14th-17th March 2012

    Download poster

  • Lu G et al.

    Nov 2011

    A user-friendly physiologically-based pharmacokinetic (PBPK) brain model and its application in simulating drug disposition in brain.
    26th JSSX Annual Meeting
    Hiroshima, Japan, 16th-18th November 2011

    Download poster

  • Abduljalil K et al.

    Nov 2011

    Predicting the effect of CYP2D6 polymorphism on pharmacodynamic response to metoprolol.
    PKUK 2011
    Durham, UK, 9th-11th November 2011

    Download poster

  • Darwich AS et al.

    Oct 2011

    Development and application of an in silico pharmacokinetic 'post bariatric surgery model' in a morbidly obese population to assess drug absorption and metabolism from the gastrointestinal tract.
    AAPS Annual Meeting
    Washington DC, USA, 23rd-27th October 2011

    Download poster

  • Turner D et al.

    Oct 2011

    A mechanistic model for the prediction of human-equilibrium blood-to-plasma concentration ratio (B/P): basic and neutraL drugs.
    AAPS Annual Meeting
    Washington DC, USA, 23rd-27th October 2011

    Download poster

  • Pade D et al.

    Oct 2011

    A performance evaluation of Simcyp Dog - a fully mechanistic physiologically-based pharmacokinetic dog model - based upon a variety of celecoxib IV and oral formulations.
    AAPS Annual Meeting
    Washington DC, USA, 23rd-27th October 2011

    Download poster

  • Neuhoff S et al.

    Oct 2011

    P-gp efflux has no impact on dose proportionality of digoxin bioavailability over a dose range of 0.125 to 1.5 mg: the outcome of a new PBPK model, that includes the in vitro transporter information, is consistent with the clinical observations.
    Annual Congress for Clinical Pharmacology
    Zurich, Switzerland, 20th-22nd October 2011

    Download poster

  • Cubitt HE et al.

    Oct 2011

    An investigation into the prediction of in vivo clearance for a range of aldehyde oxidase substrates using a mechanistic population-based pharmacokinetic model.
    17th North American ISSX Meeting
    Atlanta GA, USA 16th-20th October 2011

    Download poster

  • Pade D et al.

    Aug 2011

    A performance evaluation of Simcyp Dog - a full mechanistic physiologically based pharmacokinetic dog model - based upon a variety of theophylline IV and oral formulations.
    8th World Congress on Alternative & Animal Use in the Life Sciences
    Montreal, Canada, 21st-25th August 2011

    Download poster

  • Harwood M et al.

    Jun 2011

    Prediction of diclofenac pharmacokinetics using earl drug discovery in vitro data in a mechanistic dog physiologicallybased pharmacokinetic model - 'Simcyp Dog'.
    3rd Pharm Sci Fair
    Prague, Czech Republic, 13th-17th June 2011

    Download poster

  • Cubitt HE et al.

    Jun 2011

    Sources of inter-individual variability in IVIVE of clearance. An investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model.
    3rd Pharm Sci Fair
    Prague, Czech Republic, 13th-17th June 2011

    Download poster

  • Lu G et al.

    Jun 2011

    A physiologically-based pharmacokinetic (PBPK) brain model and its application in simulating drug disposition in brain.
    PAGE Meeting 2011
    Athens, Greece, 7th-10th June 2011

    Download poster

  • Machavaram K et al.

    May 2011

    Predicting the effect of interlukin-6, an inflammatory cytokine, on time-dependent reduction of cyclosporine clearance: an application of the Simcyp Population-Based Simulator to suppression of CYP450 by biologics.
    AAPS National Biotechnology Conference
    San Francisco CL, USA, 16th-18th May 2011

    Download poster

  • Barter ZE et al.

    Apr 2011

    Prediction of differences in pharmacokinetics between Chinese and Caucasian populations using a mechanistic physiologically-based pharmacokinetic model.
    4th Asia Pacific ISSX Meeting
    Tainan City, Taiwan, 22nd-26th April 2011

    Download poster

  • Machavaram K et al.

    Apr 2011

    Modelling the effect of interleukin-6, an inflammatory cytokine, on time-dependent reduction of cyclosporine clearance: an application of the Simcyp Population-based Simulator to suppression of CYP450 by biologics.
    ACoP 2011 Meeting
    San Diego CA, USA, 3rd-7th April 2011

    Download poster

  • Polak S et al.

    Apr 2011

    Combining in vitro-in-vivo extrapolation (IVIVE) and physiologically-based pharmacokinetics (PBPK) with drug related risk assessment: putting pieces together for a priori assessment of the likelihood of cardiotoxicity.
    ACoP 2011 Meeting
    San Diego CA, USA, 3rd-7th April 2011

    Download poster

  • Darwich AS et al.

    Mar 2011

    Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "advanced dissolution, absorption, metabolism (ADAM)" model.
    AAPS Workshop
    Bethesda MD, USA, 14th-16th March 2011

    Download poster

  • Lu G et al.

    Mar 2011

    Physiologically-based pharmacokinetics (PBPK) with and without diffusion limited permeability: modelling drug concentration-time profile in brain.
    AAPS Workshop
    Bethesda MD, USA, 14th-16th March 2011

    Download poster

  • Neuhoff S et al.

    Mar 2011

    Interplay of transport and metabolism in the gut: predictions of drug-drug interactions using physiologically based pharmacokinetic modelling.
    AAPS Workshop
    Bethesda MD, USA, 14th-16th March 2011

    Download poster

  • Rowland-Yeo K et al.

    Mar 2011

    Prediction of OAPP1B1-mediated drug-drug interaction between repaglinide and cyclosporine using physiologically based pharmacokinetic (PBPK) modelling.
    AAPS Workshop
    Bethesda MD, USA, 14th-16th March 2011

    Download poster

  • Johnson TN et al.

    Mar 2011

    A bottom-up approach to predicting the pharmacokinetics (PK) of theophylline (theo) and its interaction with fluvoxamine (fluv) in liver cirrhosis.
    112th ASCPT Meeting
    Dallas TX, USA, 2nd-5th March 2011

    Download poster

  • Rowland-Yeo K et al.

    Mar 2011

    Prediction of the increase in systematic exposure of paroxetine in patients with renal impairment.
    112th ASCPT Meeting
    Dallas TX, USA, 2nd-5th March 2011

    Download poster

  • Ghobadi C et al.

    Feb 2011

    Drug clearance in obese patients: shall we expect variations?
    National Obesity Forum, Northwest Chapter Obesity Training Day
    Salford, UK, 1st February 2011

    Download poster

  • Almond L et al.

    Nov 2010

    Simulation of virtual human subjects to investigate the impact of CYP2C19*17/*17 on omeprazole exposure.
    PSWC / AAPS Meeting
    New Orleans LA, USA, 13th-19th November 2010

    Download poster

  • Pade D et al.

    Nov 2010

    Prediction of Vss and tissue concentration-time profiles for four benzodiazepines using physicochemical, in vitro and experimental data in rat using a mechanistic PBPK model.
    PSWC / AAPS Meeting
    New Orleans LA, USA, 13th-19th November 2010

    Download poster

  • Lu G et al.

    Sep 2010

    A time-varying physiologically-based pharmacokinetic model of caffeine during pregnancy.
    DMDG Meeting
    Canterbury, UK, 15th-17th September 2010

    Download poster

  • Pade D et al.

    Sep 2010

    Prediction of Vss and tissue concentration-time profiles for four benzodiazepines using physicochemical, in vitro and experimental data in rat using a mechanistic PBPK model.
    11th Annual Simcyp Consortium Meeting
    Sheffield, UK, 19th-21st September 2010

    Download poster

  • Mishra H et al.

    Sep 2010

    Prediction of human intestinal metabolism of CYP3A substrates using the Advanced, Dissolution, Absorption and Metabolism (ADAM) Model.
    11th Annual Simcyp Consortium Meeting
    Sheffield, UK, 19th-21st September 2010

    Download poster

  • Salem F et al.

    Jun 2010

    Predicting pharmacokinetics for two NSAIDs commonly used in paediatrics using a physiologically-based model: comparing in vitro data, in vivo data from adults, or their combination as input parameters.
    CAPKR Annual Research Meeting
    Manchester, UK, 24th-25th June 2010

    Download poster

  • Salem F et al.

    Sep 2009

    Comparison of in vitro and in vivo metabolic clearance estimates for the prediction of caffeine and theophylline pharmacokinetics in adults, children and neonates using a physiologically based model.
    DMDG Meeting
    Cambridge, UK, 17th September 2009

    Download poster

  • Polak S et al.

    Sep 2009

    Prediction of human pharmacokinetics following dermal administration: intergration of a skin absorption module to the Simcyp Population-Based ADME Simulator with the aim of avoiding animal studies.
    7th World Congress on Alternative & Animal Use in the Life Sciences
    Rome, Italy, 30th August-3rd September 2009

    Download poster

  • Neuhoff S et al.

    Feb 2009

    The effect of p-glycoprotein (MDR1/ABCB1) on human gut wall absorption depends on physiochemical characteristics of the drug and dosage formulation; simulation of "fa" for digoxin, quinidine and talinolol.
    LogP 2009
    Zurich, Switzerland, 8th-11th February 2009

    Download poster

  • Yang J et al.

    Feb 2009

    Comparison of the “well-stirred” gut and the “QGut” models for predicting intestinal first-pass metabolism.
    DMDG Meeting
    Stevenage, UK, 6th February 2009

    Download poster

  • Salem F et al.

    Nov 2008

    Theoretical assessment of metabolic drug interactions in paediatric population: the impact of age related fractional metabolism (fm) and its disparity between adults and neonates.
    PKUK Meeting
    London, UK, 26th-28th November 2008

    Download poster

  • Rowland-Yeo K et al.

    Oct 2008

    Prediction of time-dependent CYP3A4-mediated in vivo drug-drug interactions from in vitro data using biological information on enzyme turnover implemented within a physiologically based model.
    15th North American ISSX Meeting
    San Diego CL, USA, 12th-16th October 2008

    Abstract published in:
    Drug Metabolism Reviews
    A184, 40(3), 131-132, 2008

    Download poster

  • Johnson TN et al.

    May 2008

    Prediction of the increased exposure to drugs in liver cirrhosis: a systems biology approach integrating prior information on disease with in vitro data on drug disposition.
    10th European ISSX Meeting

    Vienna, Austria, 18th-21st May

    Abstract published in:
    Drug Metabolism Reviews
    A95, 40(1), 63-64, 2008

    Download poster

  • Polak S et al.

    May 2008

    Prediction of the in vivo behaviour of modified release formulations of metoprolol from in vitro dissolution profiles using the ADAM model (Simcyp V8).
    10th European ISSX Meeting
    Vienna, Austria, 18th-21st May 2008

    Abstract published in:
    Drug Metabolism Reviews
    A72, 40(1), 45-46, 2008

    Download poster

  • Neuhoff S et al.

    May 2008

    Simulation of the effect of P-glycoprotein on drug absorption in the human gastrointestinal tract.
    10th European ISSX Meeting
    Vienna, Austria, 18th-21st May 2008

    Abstract published in:
    Drug Metabolism Reviews
    A236, 40(1), 169-170, 2008

    Download poster

  • Neuhoff S et al.

    May 2008

    In vitro-in vivo extrapolation of the clearance of drugs by glucuronidation: scaling factors for recombinant UGT1A1 data.
    10th European ISSX Meeting
    Vienna, Austria, 18th -21st May 2008

    Abstract published in:
    Drug Metabolism Reviews
    A188, 40(1), 133-134, 2008

    Download poster

  • Yang J et al.

    May 2008

    Cytochrome P450 turnover: methods for determining rates and implications for the prediction of drug interactions.
    2nd Asian Pacific ISSX Meeting
    Shanghai, China, 11th-13th May 2008

    Abstract published in:
    Drug Metabolism Reviews
    A93, 40(2), 59, 2008

    Download poster

  • Crewe HK et al.

    May 2008

    Comparison of the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9: determination of inter system extrapolation factors.
    10th European ISSX Meeting

    Vienna, Austria, 18th-21st May 2008

    Download poster

  • Perrett HF et al.

    May 2008

    What is the level of expression of CYP2D6 in human liver? Influence of different calibration standards of the estimation of CYP2D6 abundance.
    10th European ISSX Meeting
    Vienna, Austria, 18th-21st May 2008

    Download poster

  • Johnson TN et al.

    Mar 2008

    Mechanistic models of human pharmacokinetics to predict the effects of liver cirrhosis on the clearance of nine drugs.
    American Conference on Pharmacometrics
    Tucson, USA, 9th-12th March 2008

    Download poster

  • Turner D et al.

    Oct 2007

    Supersaturation properties of poorly soluble weak bases are key factors in determining oral drug absorption: a simulation study of nifedipine using the ADAM model (Simcyp V7.1).
    EUFEPS & COST B25 Conference
    Athens, Greece, 1st-2nd October 2007

    Download poster

  • Polak S et al.

    Oct 2007

    Impact of variability in estimates of drug diffusion coefficient on the prediction of fraction absorbed from the gut (fa) using the ADAM model (Simcyp V7.1).
    EUFEPS & COST B25 Conference
    Athens, Greece, 1st-2nd October 2007

    Download poster

  • Barter ZE et al.

    Sep 2007

    Experimental considerations in determining Inter System Extrapolation Factors required for prediction of human drug clearance from recombinantly expressed enzymes.
    DMDG Open Meeting.
    Cambridge, UK, 17th-19th September 2007

    Download poster

  • Jamei M et al.

    Jun 2007

    A novel physiologically-based mechanistic model for predicting oral drug absorption: the advanced dissolution, absorption, and metabolism (ADAM) model.
    4th WCDATD
    Kanazawa, Japan, 20th-22nd June 2007

    Download poster

  • Yang J et al.

    Jun 2007

    Comparison of the “well-stirred” gut and the “QGut” models for predicting intestinal first-pass metabolism.
    4th WCDATD
    Kanazawa, Japan, 20th-22nd June 2007

    Download poster

  • Perrett HP et al.

    Jun 2007

    The impact of genetic polymorphism in CYP3A5 on the pharmacokinetics of the mixed CYP3A4/5 substrates midazolam and tacrolimus assessed by clinic
    ESF-UB Conference
    Costa Brava, Spain, 2007

    Download poster

  • Perrett HP et al.

    Jun 2007

    Assessing the relevance of genetic polymorphism in CYP3A5 in the kinetics of midazolam and tacrolimus: the importance of adequate study size.
    ESF-UB Conference
    Costa Brava, Spain, 2007

    Download poster

  • Rowland-Yeo K et al.

    May 2007

    Prediction of in vivo drug interactions from in vitro enzyme kinetic data: time-based versus steady state simulations.
    PSWC 2007
    Amsterdam, Netherlands, 22nd-25th April 2007

    Download poster

  • Jamei M et al.

    May 2007

    Bias in estimates of metabolic constants when applying the Michaelis-Menten equation to drugs exhibiting atypical enzyme kinetics.
    PSWC 2007
    Amsterdam, Netherlands, 22nd-25th April 2007

    Download poster

  • Yang J et al.

    May 2007

    Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time) -based enzyme inhibition.
    PSWC 2007
    Amsterdam, Netherlands, 22nd-25th April 2007

    Download poster

  • Almond L et al.

    May 2007

    Mechanistic prediction of HIV drug-drug interactions in virtual populations from in vitro enzyme kinetic data: ritonavir and saquinavir.
    International Workshop on Clinical Pharmacology of HIV Therapy
    Budapest, Hungary, 16th-18th April 2007

    Download poster

  • Barter ZE et al.

    Oct 2006

    Prediction of the oral clearance of midazolam using in vitro data from recombinantly expressed enzymes and inter system extrapolation factors.
    14th North American ISSX Meeting
    Rio Grande, Puerto Rico, 22nd-26th October 2006

    Abstract published in:
    Drug Metabolism Reviews
    A71, 38(S2), 41, 2006

    Download poster

  • Almond LM et al.

    Oct 2006

    Prediction of the oral clearance of tolbutamimde in individuals with different CYP2C9 genotypes using in vitro enzyme kinetic data.
    14th North American ISSX Meeting
    Rio Grande, Puerto Rico, 22nd-26th October 2006

    Abstract published in:
    Drug Metabolism Reviews
    A323, 38(S2), 209-210, 2006

    Download poster

  • Almond LM et al.

    Sep 2006

    Utility of data from recombinant expressed genetic variants of CYPs in predicting the influence of genotype on in vivo drug kinetics - the case for S-Warfarin.
    35th ACCP Meeting
    Cambridge MA, USA, 17th-19th September 2006

    Abstract published in:
    Journal of Clinical Pharmacology
    A27, 46(9), 1067, 2006

    Download poster

  • Dickinson GL et al.

    Sep 2006

    Assessing the propagation of CYP2C9 polymorphism into the PK/PD of warfarin using clinical trial simulations (CTS).
    35th ACCP Meeting
    Cambridge MA, USA, 17th-19th September 2006

    Abstract published in:
    Journal of Clinical Pharmacology
    A28, 46(9), 1067, 2006

    Download poster

  • Johnson TN et al.

    Sep 2006

    Prediction of metabolic drug clearance in pediatric subjects and its sensitivity to different models for the development of CYP enzymes.
    35th ACCP Meeting
    Cambridge MA, USA, 17th-19th September 2006

    Abstract published in:
    Journal of Clinical Pharmacology
    A40, 46(9), 1070, 2006

    Download poster

  • Barter ZE et al.

    Sep 2006

    A meta-analysis of CYP3A4 abundance in human liver: use of different standards contributes to apparent heterogeneity in reported values.
    35th ACCP Meeting
    Cambridge MA, USA, 17th-19th September 2006

    Abstract published in:
    Journal of Clinical Pharmacology
    A82, 46(9), 1080, 2006

    Download poster

  • Ozdemir M et al.

    Sep 2006

    The impact of ketoconazole (KTZ) dosage regimen on midazolam clearance and its prediction using PBPK modelling.
    35th ACCP Meeting
    Cambridge MA, USA, 17th-19th September 2006

    Abstract published in:
    Journal of Clinical Pharmacology
    A18, 46(9), 1065, 2006

    Download poster

  • Rowland-Yeo K et al.

    Jun 2006

    Prediction of the inhibitory effects of ketaconazole and fluconazole on midazolam and zolpidem clearance from in vitro data using physiologically-based pharmacokinetic modelling.
    9th International Conference on Drug-Drug Interactions
    Seattle WA, USA, 20th-21st June 2006

    Download poster

  • Yang J et al.

    Jun 2006

    In-vitro stability of human recombinant cytochrome P450 enzymes.
    9th European ISSX Meeting
    Manchester, UK, 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A135, 38(1), 102, 2006

    Download poster

  • Van LM et al.

    Jun 2006

    Estimation of the kinetic parameters of mechanism-based inhibition of CYP2D6 by methylenedioxymethamphetamine (MDMA) in cryopreserved human hepatocytes.
    9th European ISSX Meeting
    Manchester, UK, 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A193, 38(1), 140-141, 2006

    Download poster

  • Van LM et al.

    Jun 2006

    Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine (MDMA): differences between expressed enzyme systems and human liver microsomes.
    9th European ISSX Meeting
    Manchester, UK, June 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A54, 38(1), 45, 2006

    Download poster

  • Perrett HF et al.

    Jun 2006

    The use of recombinantly expressed standards for immuno-quantification of hepatic CYP3A5 can result in an underprediction of CYP3A5 abundance.
    9th European ISSX Meeting
    Manchester, UK, 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A146, 38(1), 109, 2006

    Download poster

  • Johnson TN et al.

    Jun 2006

    Modelling of the age related changes of human CYP enzymes for predicting drug disposition in neonates, infants and children.
    9th European ISSX Meeting
    Manchester, UK, 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A84, 38(1), 20-21, 2006

    Download poster

  • Jamei M et al.

    Jun 2006

    Co-operativity in the in vitro kinetics of cytochrome P450 (CYP) mediated drug metabolism will have minimal impact on in vivo metabolic clearance.
    9th European ISSX Meeting
    Manchester, UK, 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A127, 38(1), 14, 2006

    Download poster

  • Heydari A et al.

    Jun 2006

    Predicting drug interactions with selective serotonin reuptake Inhibitors (SSRIs): impact of non-specific binding and active uptake.
    9th European ISSX Meeting
    Manchester, UK, 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A100, 38(1), 79, 2006

    Download poster

  • Dickinson GL et al.

    Jun 2006

    The propagation of genetic polymorphism in CYP2C9 into tolbutamide pharmacokinetics: assessment using an intergrated model.
    9th European ISSX Meeting
    Manchester, UK, 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A206, 38(1), 148, 2006

    Download poster

  • Turner DB et al.

    Jun 2006

    Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties.
    9th European ISSX Meeting
    Manchester, UK, 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A231, 38(1), 162, 2006

    Download poster

  • Ozdemir M et al.

    Jun 2006

    The impact of dose-staggering on the inhibitory effect of ketoconazole on midazolam clearance, and its prediction using physiologically-based pharmacokinetic modelling.
    9th European ISSX Meeting
    Manchester, UK, 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A103, 38(1), 81, 2006

    Download poster

  • Barter ZE et al.

    Jun 2006

    Differences in cytochrome P450 (CYP3A4) expression alone do not explain inter-individual variability in CYP3A mediated hepatic testosterone 6ß hydroxylase (TST6ßOH) activity.
    9th European ISSX Meeting
    Manchester, UK, 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A129, 38(1), 98, 2006

    Download poster

  • Almond LM et al.

    Jun 2006

    Prediction of the oral clearance of S-warfarin in CYP2C9 genotypes from in vitro enzyme kinetic data.
    9th European ISSX Meeting
    Manchester, UK, 4th-7th June 2006

    Abstract published in:
    Drug Metabolism Reviews
    A121, 38(1), 92-93, 2006

    Download poster

  • Barter ZE et al.

    Jan 2006

    Values of human hepatocellularity per gram of liver and associated variability for use in the prediction of human in vitro metabolic clearance.
    HUG Meeting
    Copenhagen, Denmark, 26th-27th January 2006

    Download poster

  • Dickinson GL et al.

    Nov 2005

    Simulations to assess the propagation of the impact of genetic polymorphism
    in CYP enzymes into PK and PD outcomes: warfarin and dextromethorphan
    as examples.
    AAPS Meeting 2005
    Nashville TN, USA, 6th-10th November 2005

    Download poster

  • Jamei M et al.

    Jun 2005

    Genetic algorithms and their applications in PK/PD data analysis.
    1st PharmSciFair
    Nice, France, 12th-17th June 2005

    Download poster

  • Howgate EM et al.

    Jun 2005

    Incorporation of inter-individual variability into the prediction of in vivo
    drug clearance.
    1st PharmSciFair
    Nice, France 12th-17th June 2005

    Download poster

  • Dickinson GL et al.

    Jun 2005

    The propagation of genetic polymorphism in CYP2C9 into warfarin pharmacokinetics: an integrated model.
    1st PharmSciFair
    Nice, France 12th-17th June 2005

    Download poster

  • Heydari A et al.

    Jun 2005

    The impact of study design on the estimation of parameters describing mechanism-based enzyme inhibition.
    1st PharmSciFair
    Nice, France 12th-17th June 2005

    Download poster

  • Lei Y et al.

    Jun 2005

    Inter-individual variability in the catalytic activity of CYP3A4 per unit of
    enzyme (kcat).
    1st PharmSciFair
    Nice, France 12th-17th June 2005

    Download poster

  • Shiran MR et al.

    Jun 2005

    Prediction of xenobiotic clearance in humans: in vitro-in vivo extrapolation (IVIVE) vs allometric scaling (AS).
    1st PharmSciFair
    Nice, France 12th-17th June 2005

    Download poster

  • Wilson ZE et al.

    Jun 2005

    Implications of the disparity in relative holo:apo-protein contents of different standards used for immuno-quantification of hepatic P450 3A4 (CYP3A4).
    1st PharmSciFair
    Nice, France 12th-17th June 2005

    Download poster

  • Ghanbari F et al.

    Jun 2005

    A critical evaluation of the experimental design in reports of mechanism based inhibition (MBI) studies and the assessment of their implication for in vitro-in vivo extrapolation (IVIVE).
    1st PharmSciFair
    Nice, France 12th-17th June 2005

    Download poster

  • Jamei M et al.

    Apr 2005

    Inter- and intra-individual variability in gastro-intestinal physiology has significant effects on the prediction of fraction of dose absorbed (fa).
    3rd WCDATD
    Barcelona, Spain, 18th-20th April 2005

    Download poster

  • Jamei M

    Nov 2004

    Genetic algorithms and their applications in PK/PD data analysis
    Pharmacokinetics UK 2004
    Belfast, UK, 17th-18th November 2004

  • Jamei M et al.

    Feb 2004

    Inter and intra-individual variability in physiological parameters of gastro-intestinal tract has significant effects on the predicted fraction of dose absorbed.
    LogP 2004
    Zurich, Switzerland, 29th February-4th March 2004

    Download poster

  • Yang J & Rostami-Hodjegan A

    Feb 2004

    Accounting for first pass gut metabolism improves the relationship between lipophilicity and in vivo permeability.
    LogP 2004
    Zurich, Switzerland, 29th February-4th March 2004

  • Howgate EM et al.

    Jun 2003

    Prediction drug clearance allowing for the influence of P-glycoprotein activity using SIMCYP.
    The Proceedings of the 6th Congress of European Association for Clinial Pharmacology and Therapeutics
    152, June 24th-28th 2003, Istanbul

  • Proctor NJ et al.

    Jun 2002

    Population clearance prediction of 13 drugs using SIMCYP.
    Pharmacologist
    44 (Supplement 1), LB87, 2002

  • Yang J et al.

    Jul 2001

    Prediction of fluconazole interaction with midazolam and triazolam: incorporating population variability.
    Proceedings of the British Pharmacological Society
    July 3rd-5th 2001, Clinical Pharmacology Section, University College, Dublin.

    Abstract published in:
    British Journal of Clinical Pharmacology
    A26, 52(4), 484, 2001

    View abstract and full text options

  • Boyle J et al.

    Jul 2001

    Reference values for human microsomal protein per gram of liver.
    Proceedings of the British Pharmacological Society
    July 3rd-5th 2001, Clinical Pharmacology Section, University College, Dublin.

    Abstract published in:
    British Journal of Clinical Pharmacology
    A10, 52(4), 471, 2001

    View abstract and full text options

  • Rostami-Hodjegan A et al.

    Nov 2000

    Incorporating interindividual variability into in vitro–in vivo extrapolation.
    7th EUFEPS Conference
    Basel, Switzerland, 13th-15th November 2000

  • Rostami-Hodjegan A

    Jul 1999

    Incorporating variability into prediction of drug-drug interactions: moving from deterministic to a stochastic approach.
    Mathematics in Medicine Initiative (MiMI), Compartmental Modelling and Pharmacokinetic Analysis
    July 20th-22nd 1999, University of Warwick, United Kingdom.

  • Tucker GT & Rostami-Hodjegan A

    Aug 1997

    Metabolic variability in populations.
    COST B1 Conference in The Population Approach
    Geneva, Switzerland, 12th-14th February 1997

    Chapter Published In:
    The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose
    Brussels, Luxembourg, 9-13, 1997

    View abstract and full text options

  • Tucker GT et al.

    Aug 1995

    The determination of drug metabolising status in vivo: pharmacokinetic and statistical issues.

    Chapter Published In:
    Advances in Drug Metabolism in Man
    Pacifici GM & Fracchia GN (eds)
    Brussels, Luxembourg, 37-55, 1995

    View abstract and full text options

  • Tucker GT et al.

    Aug 1995

    Phenotyping populations: pharmacokinetic and statistical issues.
    COST B1 Conference on Variability and Specificity in Drug Metabolism
    Besancon, France, 10th-12th May 1995

    Chapter Published In:
    COST B1: European cooperation in the field of scientific and technical research
    Alvan G et al. (eds)
    Brussels, Luxembourg, 191-203, 1995

    View abstract and full text options

  • Tucker GT et al.

    Aug 1990

    Pharmacokinetic-pharmacogenetic modeling – a basis for the display and detection of polymorphisms in drug metabolism.
    European Consensus Conference on Pharmacogenetics
    Besancon, France, 24th-25th October 1989

    Chapter Published In:
    COST B1: European cooperation in the field of scientific and technical research
    Alvan G et al. (eds)
    Brussels, Luxembourg, 59-67, 1990

    View abstract and full text options

  • Jackson PR et al.

    Aug 1990

    Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism – statistical methods.
    European Consensus Conference on Pharmacogenetics
    Besancon, France, 24th-25th October 1989

    Chapter Published In:
    COST B1: European cooperation in the field of scientific and technical research
    Alvan G et al. (eds)
    Brussels, Luxembourg, 43-52, 1990

    View abstract and full text options

box top

Workshops


Please click here to view our upcoming workshops.
see more
Need more help?

Consortium members and associates include: